These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1631610)

  • 1. Assessing the costs and benefits of medical research: the diabetic retinopathy study.
    Drummond MF; Davies LM; Ferris FL
    Soc Sci Med; 1992 May; 34(9):973-81. PubMed ID: 1631610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic retinopathy - need and demand for photocoagulation and its cost-effectiveness: evaluation based on services in the United Kingdom.
    Savolainen EA; Lee QP
    Diabetologia; 1982 Aug; 23(2):138-40. PubMed ID: 6813169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy.
    Townsend J; Buxton M
    Health Policy; 1997 Mar; 39(3):181-94. PubMed ID: 10165460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the screening and treatment of diabetic retinopathy. What are the costs of underutilization?
    Fendrick AM; Javitt JC; Chiang YP
    Int J Technol Assess Health Care; 1992; 8(4):694-707. PubMed ID: 1464489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model.
    Javitt JC; Canner JK; Frank RG; Steinwachs DM; Sommer A
    Ophthalmology; 1990 Apr; 97(4):483-94; discussion 494-5. PubMed ID: 2109299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managed care implications of age-related ocular conditions.
    Cardarelli WJ; Smith RA
    Am J Manag Care; 2013 May; 19(5 Suppl):S85-91. PubMed ID: 23725500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics.
    Javitt JC; Canner JK; Sommer A
    Ophthalmology; 1989 Feb; 96(2):255-64. PubMed ID: 2495499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of detecting and treating diabetic retinopathy.
    Javitt JC; Aiello LP
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):164-9. PubMed ID: 8554212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of diabetic retinopathy.
    Bresnick G
    Curr Opin Ophthalmol; 1990 Jun; 1(3):285-91. PubMed ID: 10149674
    [No Abstract]   [Full Text] [Related]  

  • 11. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC; Brown MM; Turpcu A; Rajput Y
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform.
    Javitt JC; Aiello LP; Chiang Y; Ferris FL; Canner JK; Greenfield S
    Diabetes Care; 1994 Aug; 17(8):909-17. PubMed ID: 7956643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia.
    Eastman RC; Javitt JC; Herman WH; Dasbach EJ; Copley-Merriman C; Maier W; Dong F; Manninen D; Zbrozek AS; Kotsanos J; Garfield SA; Harris M
    Diabetes Care; 1997 May; 20(5):735-44. PubMed ID: 9135935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical applications of cost analysis of diabetic macular edema treatments.
    Smiddy WE
    Ophthalmology; 2012 Dec; 119(12):2558-62. PubMed ID: 23062655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. United States comparative costs and absenteeism of diabetic ophthalmic conditions.
    Brook RA; Kleinman NL; Patel S; Smeeding JE; Beren IA; Turpcu A
    Postgrad Med; 2015 Jun; 127(5):455-62. PubMed ID: 25549691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for assessing the cost-effectiveness and the break-even point of clinical practice guidelines.
    Gandjour A; Lauterbach KW
    Int J Technol Assess Health Care; 2001; 17(4):503-16. PubMed ID: 11758295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten years after the Diabetic Retinopathy Study.
    Fine SL; Patz A
    Ophthalmology; 1987 Jul; 94(7):739-40. PubMed ID: 3309770
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.